Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod IV dosing regimen study in generalized myasthenia gravis
2021-002504-12Phase 3Active
- Sponsor
- argenx
- Start
- Sep 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoint: Mean of the average MG-ADL total score change from baseline during Week 1 through Week 21 by regimen arm. Started Sep 2021; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-002504-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002504-12.